The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.

Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore ...

Regeneron and Sanofi's Dupixent sBLA for treating chronic spontaneous urticaria in patients 12+ gets FDA review, with a ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by ...

The FDA has provided a date of April 18, 2025, to review the application for Dupixent to treat patients with chronic ...

Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for review the resubmission of the supplemental Biologics License ...

The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults and pediatric ...

你是否曾经听说过嗜酸性食管炎（EoE）？这种慢性炎症性疾病在儿童中尤为常见，它会导致食管受损和功能障碍。想象一下，一个孩子因为吞咽困难、胃酸反流和腹部不适而无法正常进食，这对他们的成长和发育会带来多大的影响！近日，再生元（Regeneron Pharmaceuticals）与赛诺菲（Sanofi）联合宣布，其重磅疗法Dupixent（dupilumab）已获欧盟批准用于治疗1至11岁的EoE儿童患 ...

French drug major Sanofi (SNY) and Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that the U.S. Food and Drug Administration ...

The FDA last year turned away the companies' application and asked for additional efficacy data. Regeneron and Sanofi said the resubmission adds results from an additional Phase 3 study of Dupixent in ...

分析师还提到了Regeneron最近的股票表现，称公司股价最近的回调过度。该公司的立场表明，他们认为当前的市场估值并未充分反映Regeneron的增长前景和产品管线潜力。这种对买入评级的重申意味着TD Cowen对Regeneron的股票表现持积极看法。